Journal Mobile Options
Table of Contents
Vol. 68, Suppl. 5, 2007
Issue release date: December 2007
Horm Res 2007;68:166–172

Excess Mortality in Acromegaly

Holdaway I.M.
Department of Endocrinology, Greenlane Clinical Centre, Auckland City Hospital, Auckland, New Zealand

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Increased production of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in patients with acromegaly is associated with a twofold increase in mortality compared with the general population. The range of standardised mortality rates in various studies ranges from 1.2 to 3.6. Predictors of Mortality: Multivariate analysis has indicated that post-treatment serum GH levels and, in a number of studies, serum IGF-I levels are the most powerful predictors of outcome. Normal IGF-I concentrations and random GH levels <2.5 µg/l measured by polyclonal radioimmunoassay result in optimal outcome. Other factors adversely influencing mortality include hypertension and a long interval between onset of the disorder and diagnosis. Conclusions: Analysis of recent reports suggests that adoption of treatment guidelines with appropriate post-treatment target ranges for GH and IGF-I, together with the availability of newer methods to control GH oversecretion, has significantly improved patient outcomes.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Nabarro JDN: Acromegaly. Clin Endocrinol (Oxf) 1987;26:481–512.
  2. Orme SM, McNally RJQ, Cartwright RA, Belchetz PE: Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 1998;83:2730–2734.
  3. Samani AA, Yakar S, LeRoith D, Brodt P: The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20–47.
  4. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R: Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 1980;12:71–79.
  5. Etxabe J, Gaztambide S, Latorre P, Vazquez JA: Acromegaly: an epidemiological study. J Endocrinol Invest 1993;16:181–187.
  6. Bengtsson B-A, Eden S, Ernest I, Oden A, Sjogren B: Epidemiology and long term survival in acromegaly. Acta Med Scand 1988;223:327–335.
  7. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB: Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998;83:3411–3418.
  8. Holdaway IM, Rajasoorya RC, Gamble GD: Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89:667–674.
  9. Bates AS, Van’t Hoff W, Jones JM, Clayton RN: An audit of outcome of treatment in acromegaly. Q J Med 1993;86:293–299.
  10. Shimatsu A, Yokogoshi Y, Saito S, Shimizu N, Irie M: Long-term survival and cardiovascular complications in patients with acromegaly and pituitary gigantism. J Endocrinol Invest 1998;21:55–57.
  11. Beauregard C, Truong U, Hardy J, Serri O: Long-term outcome and mortality after transsphenoidal adenectomy for acromegaly. Clin Endocrinol (Oxf) 2003;58:86–91.
  12. Wright AD, Hill DM, Lowy C, Fraser TR: Mortality in acromegaly. Q J Med 1970;34:1–16.
  13. Bengtsson B-A, Jonsson B, Nilsson B: Increased mortality in acromegaly is mainly caused by cardiovascular diseases. Abstracts 81st Annual Scientific Meeting US Endocrinol Soc 1999;P3-648.
  14. Trepp R, Stettler C, Zwahlen M, Seiler R, Diem P, Christ ER: Treatment outcomes and mortality of 94 patients with acromegaly. Acta Neurochir (Wien) 2005;147:243–251.
  15. Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, Romijn JA, Roelfsema F: Determinants of survival in treated acromegaly in a single centre: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004;89:2789–2796.
  16. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS: Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004;89:1613–1617.
  17. Swearingen B, Barker FG, Katznelson L, Biller BMK, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT: Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419–3426.
  18. Arita K, Kurisu K, Tominaga A, Eguchi K, Iida K, Uozumi T, Kasagi F: Mortality in 154 surgically treated patients with acromegaly – a 10-year follow-up survey. Endocr J 2003;50:163–172.
  19. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman U-H, Viikari J, Voutilainen E: A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 2005;90:4081–4086.
  20. Melmed S, Jackson I, Kleinberg D, Klibanski A: Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 1998;83:2646–2652.
  21. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S: Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526–529.
  22. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Von Werder K, Wass J, Giustina A: Guidelines for acromegaly management. J Clin Endocrinol Metab 2002;87:4054–4058.
  23. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JAH, Giustina A: Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005;153:737–740.
  24. Consensus Statement. Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and The Pituitary Society. J Clin Endocrinol Metab 2004;89:3099–3102.
  25. Ezzat S, Serri O, Chik CL, Johnson MD, Beauregard H, Marcovitz S, Nyomba BLG, Ramirez JR, Ur E: Canadian consensus guidelines for the diagnosis and management of acromegaly. Clin Invest Med 2006;29:29–39.
  26. Webb SM, Sucunza N, Barahona MJ: Biochemical evidence in favour of revising the Cortina criteria: J Endocrinol Invest 2005;28(11 suppl):84–86.
  27. Brada M, Burchell L, Ashley S, Traish D: The incidence of cerebrovascular accidents in patients with pituitary adenoma. Int J Radiat Oncol Biol Phys 1999;45:693–698.
  28. Mestron A, Webb SM, Astorga R, Benito P, Gaztambide S, Gomez J-M, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez J-A, Zamora J, Albareda M, Gilabert M: Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry. Eur J Endocrinol 2004;151:439–446.
  29. Bolanowski M, Zatonska K, Kaluzny M, Zielinski G, Bednarek-Tupikowska G, Bohdanowicz-Pawlak A, Daroszewski J, Szymczak J, Podgorski JK: A follow-up of 130 patients with acromegaly in a single centre. Neuroendocrinol Lett 2006;27:828–832.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50